Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6 months
Maximum Age: 6
Healthy Volunteers: f
View:
• Participants with confirmed Sickle Cell Disease.
• Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
• Willing and able to provide informed consent
• Ability to comply with study related evaluations and follow-up visits.
Locations
United States
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
Other Locations
Ghana
Korle Bu Teaching Hospital
RECRUITING
Accra
United Republic of Tanzania
Bugando Medical Centre
RECRUITING
Mwanza
Contact Information
Primary
Teresa Latham
Teresa.Latham@cchmc.org
513-803-7922
Backup
Amy Shova
Amy.Shova@cchmc.org
(513) 803-1917
Time Frame
Start Date: 2025-03-13
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 130
Treatments
Second Measles Vaccine (MV2)
Participants who receive second measles vaccine.
First Measles Vaccine (MV1)
Participants who obtain the first measles vaccine.
Related Therapeutic Areas
Sponsors
Leads: Children's Hospital Medical Center, Cincinnati
Collaborators: Thrasher Research Fund, National Institutes of Health (NIH)